Live
FierceBiotechHerantis taps Indivi for digital biomarker tech in Parkinson’s disease trialEndpoints NewsRelay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study10x Genomics NewsUnderstanding plate, droplet and microwell approaches in single-cell RNA sequencing - News-MedicalLonza NewsGlobal Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG - Yahoo Finance SingaporeFierceBiotechRelay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorderEndpoints NewsBioMarin's rare disease therapy shows no clinical benefit in Phase 3 testClinical OMICsFDA-Approved Asthma Drug Boosts Efficacy of Immunotherapy in Aggressive Cancers10x Genomics Blog10X Genomics’ SWOT analysis: stock faces profitability test - Investing.comEdwards LifesciencesEdwards Lifesciences stock (US28176E1082): heart-valve specialist in focus after latest earnings upd - AD HOC NEWSCharles RiverCharles River Laboratories stock (US1591881009): Fresh earnings and outlook keep investors focused o - AD HOC NEWSLonza NewsLonza Group AG stock (CH0013841017): pharma supplier in focus after 2025 results and dividend decisi - AD HOC NEWSLabCorpLabcorp stock (US50540R4092): Q1 results, new contracts and healthcare demand in focus - AD HOC NEWS
BioWorld Feb 11, 2026

NIH ends Xarelto arm of stroke trial due to safety, futility

NIH ends Xarelto arm of stroke trial due to safety, futility

Original
Body unavailable. Use the original source.